Literature DB >> 33052839

The role of extended lymph node dissection in patients undergoing radical cystectomy.

Victoria Dawson1, Mriganka Sinha1, Julian Smith1, Bhaskar K Somani1, James Douglas1.   

Abstract

Radical cystectomy (RC) with a pelvic lymph node dissection (LND) is the gold standard for the treatment of muscle invasive bladder cancer (MIBC) as well as for some high-risk non-muscle invasive bladder cancers. The therapeutic advantage of LND, in terms of cancer-specific survival (CSS), still divides opinion and, certainly, the question of the extent of LND at the time of cystectomy is still debated. In this article, we have reviewed the evidence supporting the practice of extending LND in order to help clinicians determine what is appropriate in their practice. There still remains a lack of prospective randomized studies addressing whether extended LND provides a survival benefit in patients undergoing RC for BC. However, there is large body of evidence that suggests there is a positive impact on the oncological outcomes in these patients without an apparent cost of unacceptable adverse events.

Entities:  

Year:  2020        PMID: 33052839      PMCID: PMC8057354          DOI: 10.5152/tud.2020.20376

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  32 in total

1.  Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival.

Authors:  Jørgen Bjerggaard Jensen; Benedicte Parm Ulhøi; Klaus Møller-Ernst Jensen
Journal:  Int J Urol       Date:  2011-11-03       Impact factor: 3.369

2.  Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer.

Authors:  John P Stein; David F Penson; Jie Cai; Gus Miranda; Eila C Skinner; Matt A Dunn; Susan Groshen; Gary Lieskovsky; Donald G Skinner
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

3.  Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis.

Authors:  J Leissner; R Hohenfellner; J W Thüroff; H K Wolf
Journal:  BJU Int       Date:  2000-05       Impact factor: 5.588

4.  Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study.

Authors:  Hassan Abol-Enein; Derya Tilki; Ahmed Mosbah; Mahmoud El-Baz; Ahmed Shokeir; Adel Nabeeh; Mohamed A Ghoneim
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

5.  Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference?

Authors:  Magnus Holmer; Pär-Ola Bendahl; Thomas Davidsson; Sigurdur Gudjonsson; Wiking Månsson; Fredrik Liedberg
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

6.  Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study.

Authors:  J Leissner; M A Ghoneim; H Abol-Enein; J W Thüroff; L Franzaring; M Fisch; H Schulze; G Managadze; E P Allhoff; M A el-Baz; H Kastendieck; P Buhtz; S Kropf; R Hohenfellner; H K Wolf
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

7.  Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy.

Authors:  Jürgen E Gschwend; Philipp Dahm; William R Fair
Journal:  Eur Urol       Date:  2002-04       Impact factor: 20.096

8.  Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference.

Authors:  D G Skinner
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

9.  [Results of the multidisciplinary treatment of invasive bladder cancer].

Authors:  M Miyakawa; K Oishi; Y Okada; H Takeuchi; K Okada; O Yoshida
Journal:  Hinyokika Kiyo       Date:  1986-12

Review 10.  The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review.

Authors:  Harman M Bruins; Erik Veskimae; Virginia Hernandez; Mari Imamura; Molly M Neuberger; Philip Dahm; Fiona Stewart; Thomas B Lam; James N'Dow; Antoine G van der Heijden; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2014-07-26       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.